These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 9515582)
1. Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum. Bodley AL; Cumming JN; Shapiro TA Biochem Pharmacol; 1998 Mar; 55(5):709-11. PubMed ID: 9515582 [TBL] [Abstract][Full Text] [Related]
2. Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum. Auparakkitanon S; Wilairat P Biochem Biophys Res Commun; 2000 Mar; 269(2):406-9. PubMed ID: 10708566 [TBL] [Abstract][Full Text] [Related]
3. Plasmodium falciparum: stage-related expression of topoisomerase I. Tosh K; Cheesman S; Horrocks P; Kilbey B Exp Parasitol; 1999 Feb; 91(2):126-32. PubMed ID: 9990340 [TBL] [Abstract][Full Text] [Related]
4. Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum. Cortopassi WA; Penna-Coutinho J; Aguiar AC; Pimentel AS; Buarque CD; Costa PR; Alves BR; França TC; Krettli AU PLoS One; 2014; 9(3):e91191. PubMed ID: 24651068 [TBL] [Abstract][Full Text] [Related]
5. Double-drug development against antioxidant enzymes from Plasmodium falciparum. Biot C; Dessolin J; Grellier P; Davioud-Charvet E Redox Rep; 2003; 8(5):280-3. PubMed ID: 14962365 [TBL] [Abstract][Full Text] [Related]
6. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library. González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898 [TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Plasmodium falciparum to glutamate dehydrogenase inhibitors--a possible new antimalarial target. Aparicio IM; Marín-Menéndez A; Bell A; Engel PC Mol Biochem Parasitol; 2010 Aug; 172(2):152-5. PubMed ID: 20399810 [TBL] [Abstract][Full Text] [Related]
8. Modulation of the growth of Plasmodium falciparum in vitro by protein serine/threonine phosphatase inhibitors. Yokoyama D; Saito-Ito A; Asao N; Tanabe K; Yamamoto M; Matsumura T Biochem Biophys Res Commun; 1998 Jun; 247(1):18-23. PubMed ID: 9636646 [TBL] [Abstract][Full Text] [Related]
9. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor. Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906 [No Abstract] [Full Text] [Related]
10. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes. Naughton JA; Nasizadeh S; Bell A Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341 [TBL] [Abstract][Full Text] [Related]
11. Partial purification of mitochondrial DNA topoisomerase II from Plasmodium falciparum and its sensitivity to inhibitors. Chavalitshewinkoon-Petmitr P; Worasing R; Wilairat P Southeast Asian J Trop Med Public Health; 2001 Dec; 32(4):733-8. PubMed ID: 12041546 [TBL] [Abstract][Full Text] [Related]
12. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Bodley AL; Shapiro TA Proc Natl Acad Sci U S A; 1995 Apr; 92(9):3726-30. PubMed ID: 7731973 [TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum avoids change in erythrocytic surface expression of phagocytosis markers during inhibition of nitric oxide synthase activity. Hempel C; Kohnke H; Maretty L; Jensen PØ; Staalsø T; Kurtzhals JA Mol Biochem Parasitol; 2014 Nov; 198(1):29-36. PubMed ID: 25454716 [TBL] [Abstract][Full Text] [Related]
14. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939 [TBL] [Abstract][Full Text] [Related]
15. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Champoux JJ Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925 [TBL] [Abstract][Full Text] [Related]
16. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria. Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase I inhibitors: camptothecins and beyond. Pommier Y Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856 [TBL] [Abstract][Full Text] [Related]
18. Stage specific detection and inhibition studies of Plasmodium falciparum telomerase. Aldous WK; Martin RK; Kyle DE Mol Biochem Parasitol; 1998 Sep; 95(2):281-5. PubMed ID: 9803419 [No Abstract] [Full Text] [Related]
19. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Jacob S; Aguado M; Fallik D; Praz F Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654 [TBL] [Abstract][Full Text] [Related]
20. The effect of camptothecin on topoisomerase I catalysis. Christiansen K; Westergaard O Ann N Y Acad Sci; 1996 Dec; 803():50-9. PubMed ID: 8993500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]